Crossmark

Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced PD-L1 ≥ 50% NSCLC: A Systematic Review and Meta-analysis

Published Online: 2026-02-05

Authors

Machado, Guilherme Franceschini

Grillo, Iago T. C.

D’ambrosio, Paula Duarte

Romao, Victoria Trasatti

Romero, Lorena Escalante

Caldonazo, Tulio

Passos, Felipe S.
License Information

Text and Data Mining valid from 2026-02-05

Version of Record valid from 2026-02-05
More Information

Article History

Received: 15 September 2025

Accepted: 14 January 2026

First Online: 5 February 2026

Disclosure

: The authors have no known conflict of interest to disclose.

Document is current